• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Mast Therapeutics - Articles and news items

sickle-cell-vepoloxamer

Mast Therapeutics initiates Phase 3 extension study of vepoloxamer in sickle cell disease

Industry news / 26 May 2015 / Victoria White

Mast Therapeutics has initiated an open-label, multicentre Phase 3 extension study of vepoloxamer (MST-188) in sickle cell disease, referred to as “EPIC-E”…

 

Win an Amazon Gift Card worth up to €100!TAKE OUR SURVEY
+ +